Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

Uniqure N.V.. (6/17/20). "Press Release: Uniqure Announces the Appointment of Leonard E. Post, Ph.D. to Its Board of Directors". Lexington, MA & Amsterdam.

Organisations Organisation Uniqure N.V. (Nasdaq: QURE)
  Group Uniqure (Group)
  Organisation 2 Canaan Partners (Group)
Products Product gene therapy
  Product 2 venture capital
Persons Person Post, Leonard E. (Len) (Vivace Therapeutics + Virtuoso Therapeutics 202006 CSO + advisor to Canaan Partners)
  Person 2 Kapusta, Matthew (Matt) (Uniqure 201612– CEO before interim CEO before CFO before AngioDynamics + Smith & Nephew)

~ Biopharma Executive Brings 35 Years of Research and Development Leadership ~

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Leonard E. Post, Ph.D. to its Board of Directors. Dr. Post, who will also chair the Company’s Research & Development Committee, has extensive biotechnology industry experience including previous global R&D leadership roles at BioMarin and Onyx Pharmaceuticals.

"It is with great pleasure that we nominate Len to the uniQure board,” stated Matthew Kapusta, chief executive officer of uniQure. “His considerable biotechnology experience, including his important work in gene therapy, are valuable assets for uniQure as we work to advance our pipeline candidates and to prepare to file for marketing authorization of etranacogene dezaparvovec in hemophilia B.”

Since 2016, Dr. Post has served as Chief Scientific Officer of Vivace Therapeutics and its sister company, Virtuoso Therapeutics, both of which are developing oncology therapeutics. From 2010 until 2016, Dr. Post served in various positions at BioMarin (NASDAQ: BMRN), including Chief Scientific Officer, during which time he oversaw the initiation of BioMarin's first gene therapy project for hemophilia A. Prior to that, Dr. Post served as Chief Scientific Officer of LEAD Therapeutics, Senior Vice President of Research & Development at Onyx Pharmaceuticals and Vice President of Discovery Research at Parke-Davis Pharmaceuticals. He is also currently an advisor to Canaan Partners.

Dr. Post is a virologist by training and did early work on engineering of herpes simplex virus as a postdoctoral fellow. He has a Bachelor of Science degree in Chemistry from the University of Michigan, and a Doctorate degree in Biochemistry from the University of Wisconsin.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, hemophilia A, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.

uniQure Contacts:


Maria E. Cantor
Direct: 339-970-7536
Mobile: 617-680-9452

Chiara E. Russo
Direct: 617-306-9137
Mobile: 617-306-9137


Tom Malone
Direct: 339-970-7558
Mobile: 339-223-8541

Record changed: 2023-06-05


Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Uniqure (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top